My main research interests are in genital and urinary cancers, leading a spectrum of clinical studies from phase I to randomised phase III. The majority of the studies are translational phase II studies investigating novel targeted and immune therapies.
The focus of our research is the tumour microenvironment and we are particularly interested in understanding the composition and function of the tumour extracellular matrix in immunosuppression. Cancer types we focus on include ovarian and breast cancers.
We study the role of growth factor receptor signalling and intracellular trafficking (movement inside cells) in tumour growth and metastasis in the view of improving cancer therapy.
My research in breast cancer focuses on the progression of in-situ to invasive disease with the aims of identifying 1) markers which can predict behaviour and 2) novel therapeutic targets.
Our research group focuses on understanding how centrosome amplification impacts tumour progression and how we can target cells with amplified centrosomes to develop new cancer therapies.
My research focuses on kinases regulating cancer cell growth and motility to understand how and when to target them with drugs. My group is currently examining the role of the PKN kinases in malignant progression.